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MeBACKGROUND The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High-Risk registry and REALISM
Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip device
(Abbott Vascular, Santa Clara, California) for mitral regurgitation (MR) in the United States.
OBJECTIVES The purpose of this study was to report 12-month outcomes in high-risk patients treated with the
percutaneous mitral valve edge-to-edge repair.
METHODS Patients with grades 3 to 4þMR and a surgical mortality risk of $12%, based on the Society of Thoracic Sur-
geons risk calculator or the estimate of a surgeon coinvestigator following pre-speciﬁed protocol criteria, were enrolled.
RESULTS In the studies, 327 of 351 patients completed 12 months of follow-up. Patients were elderly (76  11 years of
age), with 70% having functional MR and 60% having prior cardiac surgery. The mitral valve device reduced MR to #2þ
in 86% of patients at discharge (n ¼ 325; p < 0.0001). Major adverse events at 30 days included death in 4.8%,
myocardial infarction in 1.1%, and stroke in 2.6%. At 12 months, MR was #2þ in 84% of patients (n ¼ 225; p < 0.0001).
From baseline to 12 months, left ventricular (LV) end-diastolic volume improved from 161  56 ml to 143  53 ml
(n ¼ 203; p < 0.0001) and LV end-systolic volume improved from 87  47 ml to 79  44 ml (n ¼ 202; p < 0.0001). New
York Heart Association functional class improved from 82% in class III/IV at baseline to 83% in class I/II at 12 months
(n ¼ 234; p < 0.0001). The 36-item Short Form Health Survey physical and mental quality-of-life scores improved from
baseline to 12 months (n ¼ 191; p < 0.0001). Annual hospitalization rate for heart failure fell from 0.79% pre-procedure
to 0.41% post-procedure (n ¼ 338; p < 0.0001). Kaplan-Meier survival estimate at 12 months was 77.2%.
CONCLUSIONS The percutaneous mitral valve device signiﬁcantly reduced MR, improved clinical symptoms, and
decreased LV dimensions at 12 months in this high-surgical-risk cohort. (Endovascular Valve Edge-to-Edge REpair STudy
[EVERESTIIRCT]; NCT00209274) (J Am Coll Cardiol 2014;64:172–81) © 2014 by the American College of Cardiology
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ABB R E V I A T I O N S
AND ACRONYMS
DMR = degenerative mitral
regurgitation
ECL = echocardiographic core
laboratory
FMR = functional mitral
regurgitation
HF = heart failure
LVEF = left ventricular ejection
MR = mitral regurgitation
MV = mitral valve
TEE = transesophageal
echocardiography
TTE = transthoracic
echocardiography
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173I n the United States today, approximately 40,000patients per year undergo mitral valve (MV) sur-gery, mostly for treating signiﬁcant grade 3 to 4þ
mitral regurgitation (MR). Based on American College
of Cardiology/American Heart Association practice
guidelines (1,2) and the literature (3,4), surgical MV
repair or replacement is considered the treatment of
choice for patients with signiﬁcant MR who are either
symptomatic or have experienced mechanical conse-
quences of MR. Yet, some studies estimate that only
one-half of the patients with an indication for surgery
for MR actually undergo surgery (5). Although this
may be partly due to patient choice or problems in
the healthcare delivery system, many patients are
not offered surgery based on their high surgical risk
status (6). Evidence of this unmet medical need is
clearly demonstrated by the fact that only 5.6% of pa-
tients who underwent isolated MV surgery in the So-
ciety of Thoracic Surgeons (STS) database from 2008
to 2012 had an STS-predicted mortality rate of >12%
(response to a query of the STS database conducted
in December 2012 of all isolated MV surgeries be-
tween 2008 and 2012).SEE PAGE 193Globally, the percutaneous mitral valve edge-to-
edge repair device (MitraClip, Abbott Vascular, Santa
Clara, California) has been used in more than 10,000
patients to mechanically reduce MR without the in-
cisions and cardiopulmonary bypass needed for MV
surgery. Although initial MV trials included patients
with low to medium surgical risk, current usage and
evidence suggest that a primary role for the MV device
may be to treat symptomatic MR in patients who are
either unsuitable or at high risk for MV surgery (7).
The EVEREST II (Endovascular Valve Edge-to-Edge
Repair Study) clinical trial was designed to assess the
safety and efﬁcacy of MV in treating patients with
signiﬁcant MR (8). The EVEREST II trial included 2
prospective registries of high-surgical-risk patients
who received theMVdevice: the EVEREST II High-Risk
Registry (EVEREST II HRR), which enrolled 78 high-
risk patients between 2007 and 2008, and the
ongoing EVEREST II REALISM HR Continued Access
Study High-Risk arm, which has enrolled more than
300patients from2009 to the present. Both EVEREST II
HRR and REALISM HR have included symptomaticLifesciences; and receives royalties from Edwards Lifesciences. Dr. Feldman
institutional research support from Abbott, Boston Scientiﬁc, Edwards Lifesc
they have no relationships relevant to the contents of this paper to disclose
Listen to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
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Manuscript received September 7, 2013; revised manuscript received Novempatients with grades 3 to 4þ MR for whom
surgical risk for perioperative mortality was
$12%, as estimated using the STS calculator
(9) or by a surgeon coinvestigator based
on pre-speciﬁed criteria (described in the
Methods section). The inclusion/exclusion
criteria of these 2 registries were essentially
the same, allowing data from both of these
studies to be pooled and analyzed together.
The current investigation is a prospective,
multicenter evaluation of the safety and
effectiveness of theMVdevice in patients from
both of the EVEREST II high-risk studies who
had completed 12 months of follow-up.
METHODSPAT I EN T S E L ECT I ON . For inclusion in these
studies, patients had to be symptomatic with grades 3
to 4þ MR and have valve morphology meeting the
criteria necessary for MV device placement (10).
Transthoracic echocardiography (TTE) and trans-
esophageal echocardiography (TEE) screening tests
were used to establish protocol-based eligibility for
the procedure (11–14). MR severity and jet origin were
assessed by TTE. The primary regurgitant jet had to
originate from leaﬂet malcoaptation at the A2/P2 re-
gion (10). TEE was used to assess MV leaﬂet anatomy
and corroborate MR jet origin. Patients were excluded
if they had evidence of an acute myocardial infarction
within 2 weeks; a left ventricular ejection fraction
(LVEF) of #20% and/or an LV end-systolic dimension
of >60 mm; an MV area <4.0 cm2; an MV leaﬂet
anatomy that might preclude successful device im-
plantation; a history of MV leaﬂet surgery; echocar-
diographic evidence of an intracardiac mass,
thrombus, or vegetation; or active endocarditis.
For both EVEREST II HRR and REALISM HR, the
deﬁnition of high risk was a surgical mortality risk
of $12%, based on either the STS risk calculator or an
estimate by the surgeon coinvestigator following
pre-speciﬁed protocol criteria. Potentially qualifying
criteria ascertained by a surgeon coinvestigator
included porcelain aorta, mobile ascending aortic
atheroma, post-mediastinal radiation, functional
mitral regurgitation (FMR) with LVEF <40%, age of
75 years or older with LVEF <40%, previous medianis a consultant for and has received honoraria and
iences, and WL Gore. All other authors have reported
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EVEREST II
High Surgical Risk Cohort
N=351
30-Day Visit
N=342
Clinical Follow-Up (97%)
12-Month Visit
N=327
Clinical Follow-Up (93%)
Withdrawals n=5
Missing visit n=4
Withdrawals n=16
Missing visit n=8
FIGURE 1 Clinical Follow-Up and Patient Compliance
The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study)
high-surgical-risk cohort was composed of 78 patients from the EVEREST II
HRR and 273 patients from the high-risk arm of the REALISM Continued
Access Study. Complete patient accountability from baseline through
12 months is shown. Compliance rates include patients who expired before the
follow-up visit. A total of 16 patients withdrew, and 80 deaths occurred over
the 12-month period.
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174sternotomy with patent bypass graft(s), 2 previous
chest surgeries, hepatic cirrhosis, or 3 of the following
STS high-risk criteria: creatinine level >2.5 mg/dl,
previous chest surgery, age older than 75 years, or
LVEF <35%. If the patient met all inclusion and no
exclusion criteria, the percutaneous MV repair pro-
cedure as well as the options for continued medical
management and MV surgery were explained to the
patient. Patients provided signed informed consent
and were enrolled in the studies. The study pro-
tocols were approved by the U.S. Food and Drug
Administration, and the Institutional Review Board
at the participating institutions reviewed the
informed consent document (EVEREST II is regis-
tered at www.clinicaltrials.gov; NCT00209274).
All pre-procedure, post-procedure, and follow-up
TTEs were reviewed and analyzed by a central inde-
pendent echocardiographic core laboratory (ECL)
(University of California, San Francisco, California; or
MedStar Health Research Institute, Washington, DC)
using American Society of Echocardiography criteria
(15,16).
STAT I S T I CA L ANALYS I S . Continuous data are
summarized as mean  SD and evaluated using thepaired t-test. Categorical data are summarized as
proportions and evaluated using the Fisher exact test.
Paired binary data are evaluated using the McNemar
test, whereas paired ordinal data were evaluated us-
ing the Bowker test. The Kaplan-Meier method was
used for survival analysis. The 97.5% upper conﬁ-
dence boundary for the 30-day mortality rate was
compared to the mean surgical risk as determined by
the STS calculator. The rate of hospitalization for
heart failure (HF) was estimated and evaluated using
a Poisson regression model. In all analyses, a p value
<0.05 was considered statistically signiﬁcant.
RESULTS
Analyses included data from 351 patients enrolled in
either EVEREST II HRR (n ¼ 78) or REALISM HR
(n ¼ 273). Data were presented to the U.S. Food and
Drug Administration’s Circulatory System Devices
Panel on March 20, 2013. Of the 351 patients, 342 pa-
tients (97.4%) had 30-day clinical follow-up available,
and 327 patients (93.2%) had 1-year clinical follow-up
available (Fig. 1).
All 351 patients met protocol entry criteria for high
surgical risk: 151 patients (43.0%) had an STS score of
at least 12%, and 200 patients (57.0%) had an STS
score <12% but had at least 1 of the protocol-deﬁned
risk factors, which characterized the patient as high
risk. Among the 200 patients with an STS score <12%,
83 (41.5%) had at least 2 of the 9 pre-deﬁned risk
factors. In addition to having at least 1 of the protocol-
deﬁned risk factors, patients also had risk factors
such as cancer, acquired immunodeﬁciency syn-
drome, end-stage renal disease, or connective tissue
disease. All 351 patients were conﬁrmed to be at high
risk of surgical mortality by a cardiothoracic surgeon.
Overall, the mean STS-predicted mortality risk was
11.3  7.7% for all 351 patients. Baseline demographics
are listed in Table 1. Patients were elderly, with
an average age of 76  11 years, and presented
with primarily FMR (70.1%). The majority of patients
had a history of congestive HF (98.0%) and coronary
artery disease (82.2%), as well as other signiﬁcant
comorbidities including a history of atrial ﬁbrillation
(68.5%), angina (50.8%), hypertension (89.5%), and
cardiac surgery (59.8%). Eighty-ﬁve percent of pa-
tients were symptomatic, with New York Heart As-
sociation (NYHA) functional class III or IV.
MITRACLIP PROCEDURE
Of the 351 patients, 15 patients (4.3%) had no Mitra-
Clip device implanted, 201 patients (57.3%) had 1 MV
device implanted, and 135 (38.5%) had 2 MV devices
implanted. In 12 of the 15 patients, the MV device was
TABLE 1 Patient Demographics
EVEREST Integrated
High-Risk Cohort (N ¼ 351)
Age, yrs 75.7  10.5 (351)
Patients over 75 yrs of age 58.1 (204/351)
Male 61.0 (214/351)
Body mass index, kg/m2 26.9  11.6 (351)
Congestive heart failure 98.0 (344/351)
Coronary artery disease 82.2 (287/349)
Myocardial infarction 50.7 (177/349)
Angina 50.8 (168/331)
Atrial ﬁbrillation 68.5 (217/317)
Cerebrovascular disease 20.5 (72/351)
Stroke 12.8 (45/351)
Peripheral vascular disease 19.0 (66/348)
Cardiomyopathy 57.5 (202/351)
Chronic obstructive pulmonary disease 28.9 (101/350)
Hypertension 89.5 (314/351)
Diabetes 39.4 (138/350)
Moderate to severe renal disease 30.5 (107/351)
Functional MR causes 70.1 (246/351)
Previous cardiovascular surgery 59.8 (210/351)
Previous percutaneous coronary
intervention
49.9 (175/331)
Cardiac rhythm device implant
Pacemaker 20.3 (69/340)
Implantable cardioverter-deﬁbrillator 30.0 (102/340)
NYHA functional class
I 2.6 (9/351)
II 12.5 (44/351)
III 61.5 (216/351)
IV 23.4 (82/351)
LV ejection fraction 47.5  14.2 (318)
LV internal diameter (systole, cm) 4.4  1.1 (323)
Values are mean  SD (n) or % (n/N).
LV ¼ left ventricular; MR ¼ mitral regurgitation; NYHA ¼ New York Heart
Association.
TABLE 2 Major Adverse Events at 30 Days and at 12 Months
EVEREST High-Risk Cohort
(N ¼ 351)
30 Days 12 Months
Death 4.8 (17/351) 22.8 (80/351)
Myocardial infarction 1.1 (4/351) 2.3 (8/351)
Reoperation for failed surgical
repair or replacement
0.0 (0/351) 0.0 (0/351)
Nonelective cardiovascular
surgery for adverse events
0.3 (1/351) 0.3 (1/351)
Stroke 2.6 (9/351) 3.4 (12/351)
Renal failure 1.7 (6/351) 5.4 (19/351)
Deep wound infection 0.0 (0/351) 0.0 (0/351)
Ventilation >48 h 2.8 (10/351) 5.4 (19/351)
Gastrointestinal complication
requiring surgery
0.3 (1/351) 1.4 (5/351)
New onset of permanent
atrial ﬁbrillation
0.3 (1/351) 0.3 (1/351)
Septicemia 0.9 (3/351) 4.3 (15/351)
Blood transfusion $2 U 13.4 (47/351) 22.5 (79/351)
Total* 18.8 (66/351) 37.6 (132/351)
Total* (excluding
blood transfusions $2 U)
9.1 (32/351) 27.9 (98/351)
Values are % (n/N). *Total number of patients may not equal the sum of patients
in each row because 1 patient may experience multiple events.
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175not implanted due to an inability of the operator to
grasp the MV leaﬂets during implantation. The
remaining 3 patients did not have a device implanted
because of cardiac tamponade that occurred during
transseptal puncture; vascular complication; and
right atrial thrombus identiﬁed during the TEE, which
resulted in the procedure being aborted. No intra-
procedural death occurred, and there was no imme-
diate conversion to surgery. Mean procedure time
was 157  72 min, and mean ﬂuoroscopy time was 43
 24 min.
HOSPITAL STAY AND DISCHARGE. Post-procedure,
patients stayed in intensive care for an average of
37  61 h, and the mean hospital stay was 3.2  4.9
days. Most commonly, patients were discharged
home (322 of 351 [91.7%]), 5.7% (20 of 351) were
transferred to other care facilities, and the remaining
2.6% (9 of 351) either died in hospital or their datawere missing. At discharge, 84.6% (275 of 325) of pa-
tients achieved at least 1 grade reduction in MR,
as determined by the ECL, and 85.8% (279 of 325)
of patients had an MR reduction to #2þ.
MAJOR ADVERS E EVENT S AT 30 DAYS AND
AT 1 2 MONTHS . Death within 30 days of MitraClip
procedure occurred in 4.8% (17 of 351) of patients.
Of the 17 deaths, 5 occurred in patients that experi-
enced a stroke, 2 occurred in patients who experi-
enced a post-procedure myocardial infarction, 2
were related to vascular complications associated
with arterial access in the contralateral groin, 1 was
related to a gastrointestinal complication, 1 was
related to renal failure, 1 was related to intrapro-
cedural cardiac tamponade, and the 5 remaining
deaths were related to underlying patient comor-
bidities. None of the deaths was related to a device
malfunction. The 97.5% upper conﬁdence boundary
for 30-day mortality was 7.6%, which was lower
than the predicted STS mortality. Additional 30-day
major adverse event rates were low (Table 2). The
most common adverse event was transfusion of at
least 2 U of blood occurring in 13.4% of patients, the
majority of which was given for bleeding related to
access during the procedure. Additional transfusions
were given prophylactically or due to anemia.
Of the 9 strokes that occurred within 30 days, 7
were ischemic and 2 were hemorrhagic. Strokes
occurred in patients with a median age of 78 years
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FIGURE 2 Kaplan-Meier Freedom From All-Cause Mortality Compared
With Age-Matched Control Subjects
A total of 80 deaths (22.8%) were reported within 12 months of the
procedure. The Kaplan-Meier estimate of freedom from mortality at
12 months was 77.2% (95% conﬁdence interval: 72.4% to 81.4%).
TABLE 3 MitraClip Device Complications
EVEREST High-Risk Cohort
(N ¼ 351)
Early Phase
(Through 30 Days)
Late Phase
(>30 Days)
Single leaﬂet device
attachment rate
1.7 (6/351) 0.6 (2/351)
Mitral valve surgery 0.3 (1/351) 0.6 (2/351)
Second MitraClip procedure 1.1 (4/351) 0.0 (0/351)
MitraClip embolization 0.0 (0/351) 0.0 (0/351)
Mitral valve stenosis 0.0 (0/351) 0.9 (3/351)
Values are % (n/N).
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176and a mean predicted mortality score of 19.9%. Four
of the strokes occurred in patients with a history
of cerebral vascular accidents and/or chronic atrial
ﬁbrillation. Seven strokes were fatal, and 2 resolved.
None was determined to be due to the device or air
embolization.
Major vascular complications were notably infre-
quent, occurring in 12 patients (3.4%), consisting of 4
hematomas, 5 access site repairs, and 3 arteriovenous
ﬁstulas.
At 12 months, Kaplan-Meier freedom from death
was 77.2% (95% conﬁdence interval [CI]: 72.4% to
81.4%) (Fig. 2) and freedom from MV surgery was
97.8%. Between 30 days and 12 months, 63 patients
died, of which 64% were assessed as cardiac related
and the remaining 36% were assessed as noncardiac
related, reﬂecting the overall comorbid nature of
these patients.
Few additional complications occurred between
30 days and 12 months. The 1-year stroke rate was
3.4%, which was expected considering that 69% of
the population had a history of atrial ﬁbrillation.
Other event rates remained low, with the most com-
mon event being transfusion of at least 2 U of
blood (Table 2). Transfusions administered beyond
30 days were most often for bleeding unrelated to the
MitraClip procedure or for anemia, with only 1
transfusion administered after 30 days for access site
bleeding.DEV I C E COMPL I CA T ION S . Complications spe-
ciﬁcally related to the device occurred at a low rate
(Table 3). No case of device embolization occurred.
Single-leaﬂet device attachment occurs when the
device is attached to only 1 of the 2 MV leaﬂets.
Through 12 months, single-leaﬂet device attachment
occurred in 8 patients, with most occurring early
(<30 days). Of these 8 patients, 1 had no further
intervention, 3 had successful MV surgery, and 4
underwent a successful second procedure. Six of the
7 secondary interventions had successful MR reduc-
tion to grade #2þ. No device embolization occurred.
Mitral stenosis (deﬁned as MV area <1.5 cm2) occurred
in 1 patient between 30 days and 12 months, requiring
no further intervention.
E F F EC T I V ENE S S AT 1 2 MONTHS . Effectiveness
of the procedure, deﬁned as MR reduction to grade
#2þ, is presented in Figure 3. As measured by the
ECL, in patients with paired data at baseline and
follow-up, MR grade improved over baseline to #2þ
in 279 of 325 (85.8%) of patients at discharge and 188
of 225 (83.6%) of patients at 12 months. MR grade
improvements observed in patients with paired data
across all 3 time points (i.e., at baseline, discharge,
and 12 months) are similar: 200 of 223 patients
(89.7%) had MR #2þ at discharge, and 186 of 223
patients (83.4%) had MR #2þ at 12 months. At 12
months, MR grade was <2þ in 81 of 223 patients
(36.3%). NYHA functional class improved in most
patients (Table 4, Central Illustration). Physical and
mental quality-of-life scores improved signiﬁcantly
from baseline to 12 months (Table 4, Fig. 4). LV end-
systolic and end-diastolic volumes were signiﬁcantly
reduced from baseline to 12 months (Table 4). The
rate of HF hospitalizations decreased signiﬁcantly
from 0.79 in the 12 months before the procedure to
0.41 in the 12 months after the procedure. The pro-
portion of patients hospitalized for HF was reduced
from 42.5% (149 of 351) to 19.8% (67 of 338) (Table 5).
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FIGURE 3 Mitral Regurgitation Grade
Change in mitral regurgitation severity is shown at baseline, discharge,
and 12 months, using paired analysis.
TABLE 4 Clinical Results
Baseline 12 Months p Value*
MR grade #2þ 14.2 (32/225) 83.6 (188/225) <0.0001
NYHA functional class III to IV 82.1 (192/234) 17.1 (40/234) <0.0001
SF-36 quality of life
Physical component score 34.0  9.1 (191) 38.8  11.3 (191) <0.0001
Mental component score 44.9  13.5 (191) 49.8  12.2 (191) <0.0001
LV end-diastolic volume, ml 160.5  55.9 (203) 142.6  53.1 (203) <0.0001
LV end-systolic volume, ml 87.0  46.8 (202) 78.9  43.9 (202) <0.0001
Ejection fraction, % 48.4  14.0 (202) 47.5  13.4 (202) 0.16
Values are % (n/N) or mean  SD (n). *All p values are based on data for surviving patients with baseline
and 12-month data.
SF-36 ¼ 36-item Short Form Health Survey; other abbreviations as in Table 1.
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177OUTCOMES BY DEGENERATIVE MR AND FMR
CAUSES. Both FMR and degenerative mitral regurgi-
tation (DMR) causes were represented in EVEREST II
HRR and REALISM HR, with FMR present in the
majority of patients (70.1%) (Table 1). Safety and
effectiveness outcomes also were examined by MR
cause (Table 6). DMR patients were older, on
average, than FMR patients (by 9 years), but the 2
groups were otherwise comparable. Safety outcomes
were similar between the 2 groups, and both of the
groups experienced improvements in effectiveness
measures.
DISCUSSION
Results of the randomized, controlled EVEREST II
trial, comparing percutaneous device repair with
MV surgery in surgical candidates, were reported by
Feldman et al. (11), with durability reported recently
through 4 years (17). Most patients in EVEREST II had
DMR. Initial results from clinical experience with the
MV device in high-surgical-risk patients were re-
ported by Whitlow et al. (18). The present study was
limited to symptomatic patients with moderate to
severe or severe MR at high risk for MV surgery. The
high-risk nature of the patients in this series is sup-
ported by the low rate of MV surgery (2.2%) at 12
months, despite 16.4% of patients who had MR >2þ at
12 months. There has been some criticism of using the
STS MV replacement score rather than MV repair
score to select patients in this series. However, ac-
cording to the STS database, among patients who had
an STS-predicted mortality of >12% and who under-
went isolated MV surgery between 2008 and 2012,
85% underwent MV replacement (response to a query
of the STS database conducted in December 2012 of all
isolated MV surgeries between 2008 and 2012).
The current study results show that patients who
are at very high risk and are either ineligible or mar-
ginal candidates for surgery can be successfully
treated with the MV device, with morbidity and
mortality less than that predicted for surgery using a
well-validated surgical risk calculator. Additionally,
patients remained in the hospital for an average of
only 3 days post-procedure, and 91% of patients were
discharged home. These high-risk patients experi-
enced beneﬁt from the procedure at 12 months as
shown by signiﬁcant reduction in MR, improvement
in HF symptoms, reduction of HF hospitalization,
and reduction of LV dimensions, despite extensive
comorbidities that included extensive cardiac and
noncardiac diseases. Concerns have been raised that
high-risk patients might not beneﬁt from an inter-
vention such as the MV device either because ofexcessive periprocedural morbidity and mortality or
because of signiﬁcant residual comorbidity that might
threaten length and quality of life. These data suggest
that this population of high-risk patients can achieve
signiﬁcant improvement in quality of life with rela-
tively little morbidity. Continuing advances in pa-
tient selection, patient management, and the
procedure itself may further reduce this morbidity.
The patient demographics and results reported in
the current study are similar to the recently pub-
lished 1-year results of the Access-EU post-market
registry (7), although the EVEREST II high-surgical-
risk patients described here were slightly sicker
than those in ACCESS-EU and more often had FMR
(7). Overall, however, the safety and effectiveness
results in the 2 studies are comparable, and both of
the studies have signiﬁcant clinical implications
about the role of the MV device in real-world
practice.
CENTRAL ILLUSTRATION Symptoms of Heart Failure (NYHA
Functional Class) at Baseline, 30 Days, and 12 Months After
Percutaneous MitraClip Placement in High-Risk Patients
In high-risk patients with severe mitral regurgitation, percutaneous MitraClip
therapy signiﬁcantly improved New York Heart Association (NYHA) functional
class at 30 days and at 12 months relative to baseline (p < 0.001).
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in a narrowly deﬁned group of patients based on
speciﬁc surgical risk factors and speciﬁc anatomic
suitability for the MV device. Whether the results can
be generalized to even higher-risk patients with life
expectancies of <12 months is uncertain. At some70
60
50
40
30
20
10
0
Physical Component Score
Qu
al
ity
 o
f L
ife
 S
co
re
 (M
ea
n±
SD
)
p<0.0001
34.0 38.8
Baseline 12 Months
Paired D
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Change in the 36-item Short Form Health Survey (SF-36) physical and m
analysis.point, the net value of a procedure like MitraClip
might be less signiﬁcant in moribund patients with
other life-threatening conditions that cannot be
treated. Further reﬁnement in all patient selection
criteria such as FMR versus DMR, severe pulmonary
hypertension, right ventricular dysfunction, tricuspid
regurgitation, severe obstructive/restrictive lung
disease, dialysis, patient frailty, and a range of ejec-
tion fraction that is suitable for the MV device need
to be examined in larger studies with greater numbers
in each of these subsets and/or appropriate controls.
This study provides only 12 months of data, leaving
concerns that MV repair without ring stabilization
of the mitral annulus could diminish the long-term
beneﬁts of percutaneous repair. In these high-risk pa-
tients, the results of MV device placement appear to
be very stable from 30 days to 12months. Other studies
have reported stable results up to 4 years (17). Long-
term results beyond 10 years will be of less concern in
these high-risk patients with limited life expectancy.
There was no parallel surgical or medical control
group in this study. While critics consider this a lim-
itation, there are some challenges that justify the
absence of a prospective control group in the patient
population described. In the current report, percuta-
neous device is evaluated in both high-risk DMR and
FMR patients. Surgical repair or replacement is the
treatment of choice for patients with DMR who are
suitable MV surgical candidates, with little role for
medical therapy. The safety of percutaneous repairMental Component Score
p<0.0001
44.9 49.8
Baseline 12 Months
ata (N=191)
2 Months
ental component scores from baseline to 12 months, using paired
TABLE 5 Hospitalizations for Heart Failure
Parameter
12 Months
Pre-Enrollment
Post-Discharge
Through
12 Months p Value
% of patients (n/N) 42.5 (149/351) 19.8 (67/338)* <0.0001
No. of events 277 118
Rate
(2-sided 95% CI)
0.79
(0.70–0.89)
0.41
(0.34–0.49)
<0.0001
*9 patients died, and 4 patients withdrew before discharge and thus do not provide data for post-
discharge hospitalizations.
CI ¼ conﬁdence interval.
J A C C V O L . 6 4 , N O . 2 , 2 0 1 4 Glower et al.
J U L Y 1 5 , 2 0 1 4 : 1 7 2 – 8 1 Percutaneous Mitral Valve Repair in High-Risk Patients
179in comparison to that of surgery has already been
shown in EVEREST II; it would therefore be unethical
to randomize this subset of high-risk patients to
medical treatment. In patients with FMR, however,
where the role of surgery remains unclear, a com-
parison of the MV device to medical therapy seems
justiﬁed. The positive results reported in the current
nonrandomized study, which includes a majority of
FMR patients, are therefore the basis of the ongoing
COAPT (Clinical Outcomes Assessment of the Mitra-
Clip Percutaneous Therapy for Extremely High-
Surgical-Risk Patients) trial, which will ultimately
compare outcomes of medical therapy to those ofTABLE 6 Safety and Effectiveness Outcomes by MR Cause (Degenerative or Functional)
Degenerative MR
(n ¼ 105)
Functional MR
(n ¼ 246)
Age, yrs 81.8  8.9 (105) 73.2  10 (246)
Patients over 75 yrs of age 81.0 (85/105) 48.4 (119/246)
Female 40.0 (42/105) 38.6 (95/246)
Previous coronary artery disease 74.8 (77/105) 85.4 (210/246)
Prior myocardial infarction 29.5 (31/105) 59.8 (146/244)
History of atrial ﬁbrillation 71.6 (73/102) 67.0 (144/215)
Prior stroke 9.5 (10/105) 14.2 (35/246)
Diabetes 29.5 (31/105) 43.7 (107/245)
Moderate to severe renal disease 26.7 (28/105) 32.1 (79/246)
Chronic obstructive pulmonary disease (with or without O2 at home) 28.5 (30/105) 29.0 (71/245)
Hypertension 89.5 (94/105) 89.4 (220/246)
Previous cardiovascular surgery 50.5 (53/105) 63.8 (157/246)
Previous percutaneous coronary intervention 35.2 (37/105) 56.1 (138/246)
NYHA functional class III to IV heart failure 81.9 (86/105) 86.2 (212/246)
LV ejection fraction, % 61.0  10.1 (95) 41.7  11.5 (223)
LV end systolic diameter, cm 3.4  0.8 (92) 4.7  1.0 (231)
Safety outcome
30-day mortality 6.7 (7/105) 4.1 (10/246)
30-day major adverse event 18.1 (19/105) 19.1 (47/246)
30-day major adverse event (excluding transfusions) 8.6 (9/105) 9.3 (23/246)
30-day major bleeding complication 11.4 (12/105) 8.9 (22/246)
12-month mortality 23.8 (25/105) 22.4 (55/246)
12-month major adverse event 36.2 (38/105) 38.2 (94/246)
12-month major adverse event (excluding transfusions) 26.7 (28/105) 28.5 (70/246)
Effectiveness measure
Implant success: MR grade 95 (100/105) 96 (236/246)
#1þ at discharge 48.5 (48/99) 45.1 (102/226)
#2þ at discharge 80.8 (80/99) 88.1 (199/226)
#1þ at 12 months 30.9 (21/68) 39.4 (62/157)
#2þ at 12 months 85.3 (58/68) 82.8 (130/157)
Improvement in LVEDV at 12 months, ml 18.6  22.3 (58) 17.6  35.0 (145)
Improvement in LVESV at 12 months, ml 4.3  14.7 (58) 9.6  25.7 (144)
Improvement in SF-36 physical component score at 12 months, points 6.3 (62) 4.2 (129)
Improvement in SF-36 mental component score at 12 months, points 4.3 (62) 5.3 (129)
NYHA functional class III or IV from baseline/ 12 months, % 78.9/ 12.7 (71) 83.4/ 19.0 (63)
Rate of hospitalizations for heart failure
(12 months pre-procedure/ 12 months post-discharge)
0.71/ 0.21 (105) 0.83/ 0.49 (246)
Values are mean  SD (n) or % (n/N) unless otherwise indicated.
LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; other abbreviations as in Tables 1 and 4.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with severe MR at high surgical risk, the
percutaneous MitraClip device reduced MR, improved
symptoms, and decreased LV dimensions 12 months
after deployment.
COMPETENCY IN PATIENT CARE: Patients with
severe MR, high surgical risk, and suitable mitral
anatomy should be considered for MitraClip place-
ment to reduce the severity of MR and LV volume,
improve symptoms and quality of life, and prevent
hospitalization for HF.
TRANSLATIONAL OUTLOOK 1: More information
from ongoing randomized trials is needed to clarify
the role of the MitraClip procedure in comparison to
clearly-deﬁned medical therapy in patients with
severe MR who are not candidates for surgical valve
repair or replacement.
TRANSLATIONAL OUTLOOK 2: Reﬁnement of
patient selection criteria, such as distinguishing those
with functional versus degenerative MR, reduced
LVEF, severe pulmonary hypertension, right ventric-
ular dysfunction, tricuspid regurgitation, pulmonary
disease, renal impairment, and overall frailty, are
needed to deﬁne those who stand to gain the most
beneﬁt from the MitraClip procedure.
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with FMR.
Furthermore, patients in the current study had an
unblinded control of medical therapy prior to device
implantation, with demonstrated clinical and physi-
ological improvements over time after device therapy
relative to baseline medical therapy. Although a pla-
cebo effect on quality-of-life measures cannot be
excluded, 36% of device patients had a 2-grade
improvement in NYHA functional class. In the MIR-
ACLE (Multi-center InSync Randomized Clinical
Evaluation) trial, only 6% of patients in the placebo
arm and 16% of patients in the treatment arm had a
2-grade improvement (19). Moreover, the placebo ef-
fect is unlikely to explain reductions in MR and LV
volumes. However, improvement in clinical parame-
ters was evaluated only in surviving patients with
paired data at baseline and 12 months, which may
introduce potential bias.
WhetherMV device imparts a survival beneﬁt in this
patient group is less clear from these data and merits
further study. Several studies have suggested that the
device does, on average, improve HF symptoms and
quality of life in selected patients (11,18). A survival
advantage and even symptomatic beneﬁt for any
therapymay bemore difﬁcult to establish inMR than in
aortic stenosis (20) because of the more protracted
natural history of MR, along with confounding
morbidity from conditions like atrial ﬁbrillation,
tricuspid valve disease, and biventricular dysfunction.
CONCLUSIONS
These data are unique in that they represent the
largest prospective dataset evaluating the outcomes
of percutaneous repair in symptomatic patients with
grade 3 to 4þ MR who are at high risk of mortality
with MV surgery. The MV device is feasible and
relatively safe and is effective in reducing symptoms
and improving clinical status in this high-risk groupof patients who are unlikely to receive surgery and
essentially have no other option to reduce MR.
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